New Delhi, Jan 6 (PTI) Drug firm Cipla on Monday said it has launched a mobile application designed to enable the first line of screening for asthma in India.
According to the Global Burden of Disease report, the total burden of asthma in India is estimated to be around 34.3 million.
India has a three-fold higher mortality rate and two-fold higher asthma-associated disability burden compared to the global proportion.
This can be attributed, in part, to the underdiagnosis and undertreatment of asthma.
"By leveraging the power of next-gen technologies, we are developing solutions that are fundamentally transforming patient care and enabling better diagnostic, treatment, and management outcomes," Cipla Managing Director & Global CEO Umang Vohra said in a statement.
The mobile application -- CipAir will be available on Android and will be subsequently rolled out on iOS devices, the company stated.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)













Quickly


